→ Tyme Technologies on Friday touted “substantially improved survival benefit” from its experimental drug SM-88 in a single arm study in advanced pancreatic cancer patients with progression despite treatment with at least two prior therapies, but investors did not buy into the company’s enthusiasm, causing the stock $TYME to crater about 36%. The trial was designed to enroll 115 patients, including 36 patients in the initial stage of the trial, according to clinicaltrials.gov, and the primary endpoint of the study is response rate — suggesting Tyme was being misleading about the “survival benefit” it was brandishing. The company elected to highlight that 68% of patients treated with SM-88, (19 of 28) remained alive after a median of 4.3 months of follow-up. But, only 17 patients had undergone tumor scans, and the response rate, that would come from tumor scans, was revealed much lower down in the release — 12% of patients (2 out of 17) saw tumor reductions of more than 30%. As pointed out by STAT’s Matthew Herper, the study raised important red flags, most importantly that it was impossible to conclude survival benefit based on the available data.
→ Zymeworks has collected $8 million in milestone payments as Eli Lilly submits an IND for an immuno-oncology bispecific antibody developed on its platform — the second within a six-month period, the company highlights. The partners’ licensing and collaboration agreement date back to 2014.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,100+ biopharma pros who read Endpoints News by email every day.Free Subscription